Bo Ahrén (B Ahrén, Bo Ahren)

Publication Activity (10 Years)

Years Active: 2016-2023
Publications (10 Years): 24

Top Topics

Top Venues

Journal of diabetes investigation

Diabetes, obesity & metabolism

Endocrinology, diabetes & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Bo Ahrén
Paradigm shift in the management of metabolic diseases - next generation incretin therapy. Endocrinology (2023)
Li-Nong Ji, A J Ahmann, Bo Ahrén, M S Capehorn, P Hu, Ildiko Lingvay, W Liu, Helena W Rodbard, Z Shen, C Sorli
Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once-weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1-5, 7-10 and SUSTAIN China. Diabetes, obesity & metabolism (2023)
Matthias H Tschöp, Ruben Nogueiras, Bo Ahrén
Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy. Diabetologia (2023)
Wathik Alsalim, Ola Lindgren, Bo Ahrén
Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 secretion in humans: Characteristics and regulation. Journal of diabetes investigation 14 (3) (2022)
Bo Ahrén
Glucose-dependent insulinotropic polypeptide secretion after oral macronutrient ingestion: The human literature revisited and a systematic study in model experiments in mice. Journal of diabetes investigation 13 (10) (2022)
Wathik Alsalim, Ola Lindgren, Bo Ahrén
Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 secretion in humans: Characteristics and regulation. Journal of diabetes investigation 14 (3) (2022)
Wathik Alsalim, Ola Lindgren, Bo Ahrén
Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 secretion in humans: Characteristics and regulation. Journal of diabetes investigation (2022)
Wathik Alsalim, Ola Lindgren, Bo Ahrén
Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 secretion in humans: Characteristics and regulation. Journal of diabetes investigation 14 (3) (2022)
Wathik Alsalim, Ola Lindgren, Bo Ahrén
Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 secretion in humans: Characteristics and regulation. Journal of diabetes investigation 14 (3) (2022)
Wathik Alsalim, Ola Lindgren, Bo Ahrén
Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 secretion in humans: Characteristics and regulation. Journal of diabetes investigation 14 (3) (2022)
Bo Ahrén
Glucose-lowering action through targeting islet dysfunction in type 2 diabetes: Focus on dipeptidyl peptidase-4 inhibition. Journal of diabetes investigation 12 (7) (2021)
Bo Ahrén, Giovanni Pacini
Glucose effectiveness: Lessons from studies on insulin-independent glucose clearance in mice. Journal of diabetes investigation 12 (5) (2020)
Ola Lindgren, Bo Ahrén
Consequences on islet and incretin hormone responses to dinner by omission of lunch in healthy men. Endocrinology, diabetes & metabolism 3 (3) (2020)
Bo Ahrén, Yuichiro Yamada, Yutaka Seino
The Incretin Effect in Female Mice With Double Deletion of GLP-1 and GIP Receptors. Journal of the Endocrine Society 4 (2) (2019)
Wathik Alsalim, Olga Göransson, Andrea Tura, Giovanni Pacini, Andrea Mari, Bo Ahrén
Persistent whole day meal effects of three dipeptidyl peptidase-4 inhibitors on glycaemia and hormonal responses in metformin-treated type 2 diabetes. Diabetes, obesity & metabolism 22 (4) (2019)
Daniela Jakubowicz, Zohar Landau, Shani Tsameret, Julio Wainstein, Itamar Raz, Bo Ahrén, Nava Chapnik, Maayan Barnea, Tali Ganz, Miriam Menaged, Naomi Mor, Yosefa Bar-Dayan, Oren Froy
Reduction in Glycated Hemoglobin and Daily Insulin Dose Alongside Circadian Clock Upregulation in Patients With Type 2 Diabetes Consuming a Three-Meal Diet: A Randomized Clinical Trial. Diabetes care 42 (12) (2019)
Wathik Alsalim, Bo Ahrén
Insulin and incretin hormone responses to rapid versus slow ingestion of a standardized solid breakfast in healthy subjects. Endocrinology, diabetes & metabolism 2 (2) (2019)
S S Ahmadi, K Filipsson, H Dimenäs, S S Isaksson, Henrik Imberg, S Sjöberg, Bo Ahrén, S Dahlqvist, T Gustafsson, J Tuomilehto, I B Hirsch, Marcus Lind
Effect of liraglutide on anthropometric measurements, sagittal abdominal diameter and adiponectin levels in people with type 2 diabetes treated with multiple daily insulin injections: evaluations from a randomized trial (MDI-liraglutide study 5). Obesity science & practice 5 (2) (2019)
Andrea Tura, Giovanni Pacini, Yuchiro Yamada, Yutaka Seino, Bo Ahrén
Glucagon and insulin secretion, insulin clearance, and fasting glucose in GIP receptor and GLP-1 receptor knockout mice. American journal of physiology. Regulatory, integrative and comparative physiology 316 (1) (2018)
Wathik Alsalim, Margaretha Persson, Bo Ahrén
Different glucagon effects during DPP-4 inhibition versus SGLT-2 inhibition in metformin-treated type 2 diabetes patients. Diabetes, obesity & metabolism 20 (7) (2018)
Bo Ahrén
Glucagon-like peptide-1 receptor agonists for type 2 diabetes: A rational drug development. Journal of diabetes investigation 10 (2) (2018)
Johan Farngren, Margaretha Persson, Bo Ahrén
Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes: A randomized, placebo-controlled study. Diabetes, obesity & metabolism 20 (8) (2018)
Bo Ahrén, Stephen L Atkin, Guillaume Charpentier, Mark L Warren, John P H Wilding, Sune Birch, Anders Gaarsdal Holst, Lawrence Alan Leiter
Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes, obesity & metabolism 20 (9) (2018)
Bo Ahrén, James E Foley
Estimation of the Relative Contribution of Postprandial Glucose Exposure to Average Total Glucose Exposure in Subjects with Type 2 Diabetes. International journal of endocrinology 2016 (2016)